Health Condition 1: M069- Rheumatoid arthritis, unspecified
Conditions
Interventions
Intervention1: Kenacort Injection: The subject will receive-
Dose: Triamcinolone Acetonide (KENACORT) Injection of 40 mg
Route of Administration: Intraarticular
Frequency : one dose through out the
Sponsors
Dr Chandrashekara S
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient has a confirmed diagnosis of Rheumatoid Arthritis and on stable therapy for RA in the last 3 months as per ACR 2010 criteria. 2. Evidence of disease flare-up in the knee joint 3. Patient on at least 1 DMARD for the past 6 month 4. Stable dose of DMARD in the last 6 weeks 5. Patients who require intra-articular glucocorticoid injection in the knee joint. 6. Participants should have the ability to understand the requirements of the study. 7. Participants willing to abide by the study restrictions and return for the required assessments. 8. Participants willing to provide an written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients not willing to give informed consent 2. Patients with only mild disease 3. Patients currently on intravenous or depo steroids. 4. In the Principal Investigatorâ??s opinion patient who may require changes in current DMARDs including its dose strength during the study duration. 5. Patients with septic arthritis 6. Any other clinically significant disorder which needs treatment or serious systemic illness 7. Alcoholics and/or drug abusers. 8. Known history of hypersensitivity to the trial drug or any of its ingredients. 9. Pregnant / lactating woman. 10. Patients who have completed participation in any other clinical trial during the past six (06) months. 11. Any other condition which the Principal Investigator thinks may jeopardize the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess and compare the mean change in severity of pain measured by VAS score from baseline to week 2 visit. To assess and compare the mean change in reduction of swelling on the Likert scale from baseline to week 2 visit. Timepoint: Week 2 | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess and compare the mean change in frequency and duration of morning stiffness from Baseline to Week 6 & Week 12 visit To compare the pattern of frequency morning stiffness between two different arms To assess and compare the mean change in severity of pain & mobility measured by VAS score from Baseline to Week 6 & Week 12 visit To assess and compare the mean change in reduction of swelling on the Likert scale from baseline to week 6 & week 12. Timepoint: week 6 and week 12 | — |
Countries
India
Contacts
Public ContactSatish Marukurthi
ChanRe Rheumatology and Immunology Center and Research
Outcome results
None listed